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Antigen presentation by major histocompatibility complex (MHC) proteins is essential for 
adaptive immunity. Prior to presentation, peptides need to be generated from proteins 
that are either produced by the cell’s own translational machinery or that are funneled 
into the endo-lysosomal vesicular system. The prolonged interaction between a T cell 
receptor and specific pMHC complexes, after an extensive search process in secondary 
lymphatic organs, eventually triggers T cells to proliferate and to mount a specific cellular 
immune response. Once processed, the peptide repertoire presented by MHC proteins 
largely depends on structural features of the binding groove of each particular MHC 
allelic variant. Additionally, two peptide editors—tapasin for class I and HLA-DM for class 
II—contribute to the shaping of the presented peptidome by favoring the binding of 
high-affinity antigens. Although there is a vast amount of biochemical and structural 
information, the mechanism of the catalyzed peptide exchange for MHC class I and 
class II proteins still remains controversial, and it is not well understood why certain 
MHC allelic variants are more susceptible to peptide editing than others. Recent studies 
predict a high impact of protein intermediate states on MHC allele-specific peptide 
presentation, which implies a profound influence of MHC dynamics on the phenomenon 
of immunodominance and the development of autoimmune diseases. Here, we review 
the recent literature that describe MHC class I and II dynamics from a theoretical and 
experimental point of view and we highlight the similarities between MHC class I and 
class II dynamics despite the distinct functions they fulfill in adaptive immunity.
Keywords: antigen presentation, major histocompatibility complex, HLA, protein dynamics, peptide exchange, 
tapasin, HLA-DM, adaptive immunity
iNTRODUCTiON
Major histocompatibility complex (MHC) class I and class II proteins play a pivotal role in the adap-
tive branch of the immune system. Both classes of proteins share the task of presenting peptides on 
the cell surface for recognition by T cells. Immunogenic peptide–MHC class I (pMHCI) complexes 
are presented on nucleated cells and are recognized by cytotoxic CD8+ T cells. The presentation of 
pMHCII by antigen-presenting cells [e.g., dendritic cells (DCs), macrophages, or B cells], on the 
other hand, can activate CD4+ T cells, leading to the coordination and regulation of effector cells. 
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In all cases, it is a clonotypic T cell receptor that interacts with a 
given pMHC complex, potentially leading to sustained cell:cell 
contact formation and T cell activation.
Major histocompatibility complex class I and class II share an 
overall similar fold. The binding platform is composed of two 
domains, originating from a single heavy α-chain (HC) in the 
case of MHC class I and from two chains in the case of MHC class 
II (α-chain and β-chain) (Figure 1A). The two domains evolved 
to form a slightly curved β-sheet as a base and two α-helices 
on top, which are far enough apart to accommodate a peptide 
chain in-between. Two membrane-proximal immunoglobulin 
(Ig) domains support the peptide-binding unit. One Ig domain is 
present in each chain of MHC class II, while the second Ig-type 
domain of MHC class I is provided by non-covalent association of 
the invariant light chain beta-2 microglobulin (β2m) with the HC. 
Transmembrane helices anchor the HC of MHC class I and both 
chains of MHC class II in the membrane (Figure 1A).
The groove in-between the two helices accommodates pep-
tides based on (i) the formation of a set of conserved hydrogen 
bonds between the side-chains of the MHC molecule and the 
backbone of the peptide and (ii) the occupation of defined pock-
ets by peptide side chains (anchor residues P2 or P5/6 and PΩ 
in MHC class I and P1, P4, P6, and P9 in MHC class II) (1–4). 
The type of interactions of individual peptide side-chains with 
the MHC depend on the geometry, charge distribution, and 
hydrophobicity of the binding groove. Predicting the affinity of 
these distinct MHC–antigen interactions for individual allotypes 
has been a long-standing goal in the community. While good 
progress has been made in developing and optimizing bioinfor-
matic algorithms to estimate peptide binding to MHC proteins, 
these in  silico predictions, however, still yield false positives 
(5, 6), and often fail in predicting immunodominance. We argue 
that understanding the relevance of transient or energetically 
excited protein conformations that are visited during the equi-
librium fluctuations of the molecular structure is important for 
making good predictions.
In MHC class I, the binding groove is closed at both ends by 
conserved tyrosine residues leading to a size restriction of the 
bound peptides to usually 8–10 residues with its C-terminal 
end docking into the F-pocket (7–9). In contrast, MHC class 
II proteins usually accommodate peptides of 13–25 residues in 
length in their open binding groove, with the peptide N-terminus 
usually extruding from the P1 pocket (10). It has been reported 
that the interactions at the F pocket region in MHC class I and the 
P1 region (including the P2 site) in MHC class II appear to have 
a dominant effect on the presentation of stable pMHC complexes 
and on the immunodominance of certain peptidic epitopes 
(11–16). Interestingly, these pockets are located at opposite ends 
of the binding groove of the respective MHC class I and MHC 
class II structures (Figure 1B).
The most polymorphic human MHC class I and class II 
proteins (human leukocyte antigens, HLAs) are each expressed 
from three gene regions (MHC class I: HLA-A, -B, -C; MHC 
class II: HLA-DR, -DP, -DQ), which are all highly polymorphic. 
This allelic variation mainly affects the nature and composition 
of the peptide-binding groove and thus modulates the peptide 
repertoire that is presented on the surface by MHC class I or 
MHC class II proteins for CD8+ or CD4+ T  cell recognition, 
respectively. A good match of the peptide and the MHC binding 
groove is an important, but certainly not the sole determinant 
of its presentation. In fact, the formation of a pMHC complex 
depends on its peptide-loading pathway, in which the selection 
of peptides is influenced by several factors, such as antigen 
availability, protease activity, or the availability of chaperones. In 
addition, for each MHC class, a “catalyst” is available to enhance 
peptide exchange for certain peptides: tapasin for MHC class I 
and HLA-DM for MHC class II. These molecules edit the pre-
sented peptide repertoire and bias the exchange reaction toward 
the presentation of thermodynamically stable complexes. Tapasin 
and HLA-DM thus act similar to typical enzymes by reducing 
the energy barrier for peptide exchange. However, in the case of 
HLA-DM and tapasin, no covalent bonds are formed or cleaved 
during the exchange reaction.
The MHC class I HC folds and assembles with β2m in the 
lumen of the endoplasmic reticulum (ER). The partially folded 
heterodimer is then incorporated into the peptide-loading 
complex (PLC) for peptide binding and exchange. In the PLC, 
tapasin is a protein that catalyzes, together with other chaperones, 
the loading of high-affinity peptides derived from proteolysis of 
endogenously expressed proteins (Figure 1C, left panel) (17, 18). 
In the absence of tapasin, some class I allotypes (such as HLA-
B*44:02) are retained in the ER (tapasin-dependent), whereas 
other class I proteins (tapasin-independent, such as HLA-B*44:05 
and HLA-B*27:09) can bind peptides and travel to the cell surface 
(19–22). There is no crystal structure of the MHC class I/tapasin 
complex, but several structural models and mutational studies 
suggested that tapasin binds two regions in the HC of MHC 
class I, a loop in the α3 domain (residues 222–229), and a region 
of the α2 domain (residues 128–137) adjacent to the F-pocket 
(Figure 1B) (18, 21, 23–29).
Major histocompatibility complex class II proteins fold in 
the ER in complex with a protein called invariant chain (Ii) (30) 
and are then transported to late endosomal compartments (also 
coined MHC class II compartment, MIIC). There, Ii is cleaved by 
cathepsin proteases and a short fragment remains bound to the 
peptide-binding groove of MHC class II proteins, termed class 
II-associated invariant chain peptide (CLIP). This placeholder 
peptide is then normally exchanged against higher affinity pep-
tides, which are derived from proteolytically degraded proteins 
available in endocytic compartments (Figure  1C, right panel). 
HLA-DM accelerates peptide exchange, with different allelic vari-
ants being more or less susceptible to catalysis. HLA-DM has a 
highly similar structural fold compared to classical MHC class II 
proteins, but its closed-up binding groove prevents peptide bind-
ing. Crystal structures of HLA-DM in complex with the MHC 
class II protein HLA-DR1 (31) and in complex with the com-
petitive inhibitor HLA-DO (32) revealed that HLA-DM mainly 
contacts the α1-domain of MHC class II proteins close to the P1 
pocket and additionally the membrane-proximal β2-domain, in 
line with previous mutational analyses (Figure 1B) (13, 33–35).
Despite the structural differences between tapasin and 
HLA-DM as well as their presumably opposite sites of interac-
tion with regard to the orientation of the binding groove, a 
similar mode of action has been suggested, hinting at a possible 
FigURe 1 | Structural characteristics of major histocompatibility complex (MHC) class i and MHC class ii proteins and their compartment-
dependent loading with processed peptides. (A) Domain topology of a pMHC class I and pMHC class II complex. (B) Structure of HLA-A68 in complex with an 
HIV-derived peptide (PDB: 4HWZ, left) and HLA-DR1 in complex with a hemagglutinin-derived peptide (1DLH, right). Indicated are the supposed interaction sites of 
MHC class I with tapasin and of MHC class II with DM as dashed gray lines. The peptide is shown in yellow with its N and C-terminus marked and relevant pockets 
are labeled green (C) Simplified illustration of MHC class I (left) and II (right) processing and peptide-editing pathways. CLIP, class II-associated invariant chain 
peptide; Caln., calnexin; Calr., calreticulin; ER, endoplasmic reticulum; PLC, peptide loading complex.
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convergent evolution of the two exchange catalysts (Figure 1B) 
(36). A common feature seems to be that both catalysts target 
regions in the vicinity of those pockets in the peptide-binding 
groove that are of great relevance for the stability of the respective 
pMHC complex (11, 13, 15, 31, 37). Furthermore, in both cases, 
the binding of a high-affinity peptide is able to release the interac-
tion with tapasin/DM (13, 26, 38, 39) and allows for transport of 
stable pMHC complexes to the cell surface.
While the general hallmarks of antigen processing and edit-
ing have been established, the discussion is now moving toward 
the dynamics of the system, both at the cellular and molecular 
level. The mechanistic questions relate to a description of how 
exactly peptides are selected for presentation and how tapasin 
and HLA-DM catalyze this reaction in an allele-specific manner.
STRUCTURAL vARiATiONS iN MHC 
COMPLeXeS
Many allelic variants of MHC class I and MHC class II bound 
to individual peptide antigens display different biochemical fea-
tures, but surprisingly, their “ground-state,” i.e., thermodynami-
cally most stable conformations reported by the many available 
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pMHC X-ray structures are very similar. In contrast, increasing 
experimental and computational evidence of wild type (WT) and 
mutant MHC complexes over the past years incontestably revealed 
that changes in conformational dynamics in MHC proteins have 
to accompany peptide loading and exchange (22, 40–46).
To highlight possible dynamic regions within ground-state 
crystal structures of human MHC class I and class II proteins 
bound to a peptide, we performed a global B-factor analysis of 
all available X-ray crystal structures of human MHC complexes 
in the absence of any other binding partner. In each structure, 
we normalized the B-factor values of each alpha carbon (CA) 
atom to the global mean. Then the variance of all the normalized 
B-factor values for each CA atom, in 297 human pMHC class 
I and 41 human pMHC class II structures, was calculated and 
depicted with a blue to red color spectrum, respectively (heat map 
on structures of HLA-A*0201 and HLA-DR1, Figures  2A,B). 
Overall in the binding groove of class I (class II), the α-helix 
in the α2 (β1) domain displays higher B-factor variation values 
than the α-helix in the α1 (α1) domain and the β-strands from 
both domains. Among the pMHCI structures, although B-factor 
variation values in the N-terminus-proximal helical segments 
indicate the existence of a certain degree of dynamics, the 
α2-helical region around the peptide C-terminus displays the 
highest variation in B-factors (Figure 2A). Among the class II 
structures, high B-factor variation values are found especially 
in β-strands 2 and 4 of the α-chain, the 310 helical region and 
almost the entire β-chain α-helix (Figure  2B). Our analysis is 
corroborated by a previous comparison of 91 different pMHC 
class II crystal structures (47). In this analysis, conformational 
heterogeneities were observed in three regions: the 310-helical 
region (α45–54), the kink region in the β1-helix (β62–71), and 
the β2-domain (β105–112).
It is known that, to some extent, structural variations can be 
introduced by variable peptide-binding modes. In this context, 
peptides longer than 8–10 residues have been reported to bind 
to the MHC class I binding groove (48–52). To accommodate 
the increase in length, the peptides have to bulge out, leaving the 
central residues (between p2 and pΩ) exposed to solvent. This is 
usually achieved by a kink in the backbone in the middle part of 
the peptide. Recently, two crystal structures of HLA-A2 bound 
to15-mer peptides have been solved (53). The two peptides 
follow a binding mode similar to that of the canonical peptides 
with two anchor residues in the B and F pockets. While one of 
the peptides showed a mobile central conformation similar to 
another reported long peptide (48, 54), the other peptide adopted 
an unusual rigid β-hairpin secondary structure. Furthermore, 
although the binding of the N- and C-termini at both ends of 
the binding groove is conserved in almost all the MHC class I 
complexes, some exceptions have been reported. For example, in 
the F pocket of HLA-A2, the C terminal residue of the peptide 
extends by ~1  Å leading to a significant rearrangement of the 
pocket with only one of the standard hydrogen bonds (at Thr143) 
preserved (55). Another example is seen in the HLA-B35 protein, 
the short N-terminus of the 8-mer peptide does not reach the A 
pocket. Instead, the hydrogen bonds between the amino group of 
P1 residue and residue 45 of MHC class I are mediated by a water 
molecule (56).
Since, in the case of MHC class II proteins, the peptide 
ligand within the binding groove usually adopts a pseudosym-
metrical PPII helix-like conformation, bidirectional binding is 
theoretically possible. An interesting case represents a crystal 
structure of a DR1/CLIP complex, in which the peptide binds 
in a very unusual, inverted orientation (C-terminus close to the 
P1 pocket). The driving force for this peptide inversion is the 
formation of three additional H-bonds of P1-close residues and 
the backbone of the peptide’s C-terminus (57, 58). Biological and 
biochemical evidence for the existence of other pMHC class II 
isomers have been described in the context of autoimmunity 
(59). Since MHC class II proteins have open binding grooves, 
peptides can protrude outwards and even bind in different 
registers. In this regard, an insulin B chain-derived peptide 
(InsB9–23) was suggested to induce type 1 diabetes (T1D) in a 
thermodynamically less favored, low-affinity binding register 
(60, 61).
Apart from variable peptide binding, catalyst binding can 
induce more significant conformational variation, as seen in 
DM-bound DR. By designing a P1-anchor-free pMHC class 
II complex, Pos et al. could increase the affinity for the pMHC 
class II to DM and solve the crystal structure for the covalently 
tethered DR1/HA/DM complex (31). In this MHC class II/DM 
complex, the interaction interface is primarily composed by 
the α-subunits of DM and DR1 (~65% of the entire interaction 
surface, Figure 1B). DM binding to DR stabilizes a rearranged 
conformation in the vicinity of the P1 pocket of DR1 resulting 
from the absence of critical peptide-MHC class II interactions 
in this region. The extended region in the DR1α-chain (α52–55) 
and the 310-helix adopt an α-helical fold (Figure 3A). Compared 
to other parts of the pMHC class II structure, it was shown 
that this site indeed represents a conformationally labile region 
(35, 46). In addition, the C-terminal part of the β1-α-helix 
(β86–91) becomes slightly less structured (Figure 3B).
A feature, which is also present in DM-bound DO, is the inter-
molecular H-bonds between two conserved residues (DRα W43 
and DMα N125). The formation of these critical bonds (as well as 
other interactions) likely depends on the “flipping out” movement 
of αW43 from the P1 pocket of DR1 toward DMα (Figure 3A). 
This movement of DR1 αW43 was suggested to be triggered by 
partial dissociation of the peptide’s N-terminus or by transient 
destabilization of contacts of the peptide N-terminus when bound 
to MHC class II (13, 64). As a consequence, the P1 site is stabilized 
by a repositioning of two phenylalanine sidechains (DRα F51 and 
DRβ F89), thereby compensating for the loss of peptide anchors 
and αW43 from this region (Figure 3B). Incoming peptides have 
to compete with these repositioned Phe residues for the P1/P2 
site in order to be selected for display. Interestingly, structural 
characteristics of T1D-conferring HLA-DQ alleles were indeed 
discussed to be linked to decreased DM-sensitivity (62). The 
analysis of several DQ variants indicated structural differences 
of the T1D-risk variants DQ2 and DQ8 when compared to DQ1, 
DQ 6, or DR variants. The decrease in DM-susceptibility of these 
two proteins was explained by a stabilization of the 310 helical 
region (63) (Figure 3C). However, the exact relationship between 
structural variations in the 310 helix and DM-susceptibility are 
not clear, as highly DM-susceptible DR complexes can display 
FigURe 2 | global B-factor analysis of X-ray crystal structures of MHC class i and MHC class ii. Shown is the variance of the normalized residual B factor 
values of CA atoms (A) derived from 297 human pMHC class I structures is plotted as blue to red spectrum on a HLA-A*0201/peptide complex (PDB: 5HHN) and 
(B) from 41 human pMHC class II structures is plotted on a DR1/peptide complex (PDB: 4X5W).
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a different conformational mode, compared to DM-susceptible 
DQ alleles (Figure 3D).
The observed changes lead to the question as to how much 
structural plasticity in these regions preexists in the peptide-
loaded form and provide a prerequisite for catalyzed as well 
as for spontaneous peptide exchange. For example, do pMHC 
complexes sample conformations observed in simulations of 
empty proteins or in complex with the catalyst? How would 
allelic variation affect the distribution of MHC proteins within 
the conformational space and thereby influence the presented 
peptide repertoire? Could variation in protein plasticity also 
account for the association of specific MHC alleles with immune 
diseases? Since the polymorphic peptide-binding groove of MHC 
proteins defines its affinity for a certain peptide, substitutions 
of even a single amino acid may lead to significantly different 
affinities for individual peptides. In general, the critical factors 
defining whether a peptide is presented or not are determined 
at the different levels of antigen processing and presentation 
such as uptake route, amount, and folding state of the antigenic 
protein, amenability to proteolytic degradation, and catalysis of 
the complex, etc. However, at the molecular level, it has been 
shown that certain polymorphisms shape individual pockets 
in the peptide-binding groove to optimally present an autoim-
munogenic self-peptide (65–67). In other cases, the functional 
impact of disease-associated polymorphisms remained enigmatic 
and suggests that dynamics might account for the observed 
differences.
DYNAMiCS OF PePTiDe-FRee MHC 
PROTeiNS
While simulations and experimental studies vary in the features 
ascribed to peptide-free MHC proteins, they certainly agree 
in attributing a substantial degree of dynamics to the peptide-
binding groove. Thus, binding of peptides to MHC proteins is 
of utmost importance for the stabilization of the known MHC 
fold (40, 68). The lack of a crystal or an NMR structure of 
peptide-free MHC protein hinders an accurate description of the 
structural changes upon peptide binding and this is probably due 
to the ensemble character of the peptide-free conformers. This 
FigURe 3 | Conformational rearrangements upon DM binding and 
structural variations in type 1 diabetes-susceptible DQ complexes.  
(A) Structural rearrangement in the α1-S4 strand and 310-helical region seen 
in DR1 when bound to DM (limon cartoon) compared to DR1 unbound DM 
(red). (B) DM-induced rearrangements in the P1-pocket and the surrounding 
helical segments. PDBs used in (A,B) 1DLH and 4FQX. (C) Overlay of DQ2/
ag (PDB: 1S9V), DQ6/hyp1–13 (PDB:1UVQ) and DQ8/InsB9–23 (PDB: 1JK8) 
showing the structural variations of the 310 helix and the P1-proximal β1-helix. 
Interdomain communication as exemplarily indicated by the hydrogen bond 
between αR52 and βE86/βT89 in the DQ8 allele variant is thought to increase 
the stability of these regions and was previously discussed to be linked to a 
lowered DM-susceptibility (62, 63). ag, αI-gliadin; hyp, hypocretin peptide 
1–13; InsB, insulin B chain 9–23. (D) Structural alignment of DR1/CLIP (PDB: 
3QXA) and DR1-αF54C/CLIP (PDB: 3QXD), a mutant that shows an altered 
conformation in the 310 helix and an increased DM susceptibility.
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ensemble character, however, has been probed by computational 
techniques, as discussed in the following paragraphs.
MHC Class i
Most of the conformational dynamics information on the 
peptide-free class I have been revealed by molecular dynamics 
(MD) simulations. In such simulations, peptide-free class I pro-
tein is modeled from the crystal structure by deleting the atoms 
of the bound peptide. In the absence of peptide, an increased 
conformational flexibility of the F pocket region was observed 
for several allelic variants (HLA-A*02:01, HLA-B*44:02, HLA-
B*44:05, HLA-B*27:05, HLA-B*27:09, H-2Db, and H-2Kb) (9, 15, 
21, 22, 69–71). Longer simulations of chicken and human class 
I allotypes showed increased global motion in the peptide-free 
form when compared to the peptide-bound proteins (72, 73). By 
combining molecular docking and MD simulations, a confor-
mational transition of the 310 helical segment of H-2Ld between 
the peptide-bound and peptide-free class I was observed. Thus, a 
conformational reorganization close to the A and B pockets upon 
peptide binding was proposed (74).
Experimentally, circular dichorism (CD) was used to measure 
the thermal denaturation temperature (Tm) of the peptide-free 
HLA-B*07:02 (B7/β2m). By increasing the temperature, a gradual 
loss of the structure-specific signal of B7/β2m in the CD spectrum 
of peptide-free class I was detected, indicating a more heteroge-
neous conformational population. Furthermore, in the absence 
of peptide, the binding groove of B7/β2m was more sensitive 
to enzymatic proteolysis when compared to the peptide-bound 
form (40). Saini et al. studied the unfolding of H-2Kb by measur-
ing the intrinsic tryptophan florescence. The results pointed to a 
folding intermediate of peptide-free class I proteins that are more 
structured than a molten globule (75). This was in line with a 
previous study arguing for a native-like conformation of in vitro 
refolded empty murine class I proteins (76).
Structural studies using NMR indicated a loss of the binding-
groove fold in the peptide-free form of a HLA-C allotype. In 
particular, NMR spectra of these peptide-free MHC class I 
protein show the loss of selected methionine NH resonances of 
the β-sheet floor of the peptide-binding groove, which indicated 
unfolding or conformational exchange of this part of the protein 
(77). This is consistent with previous reports indicating that espe-
cially the binding groove is undergoing conformational exchange 
in the absence of the bound peptide (40, 78).
A work that focused on complexes with a partly filled MHC 
class I binding groove pointed to a requirement of the stabiliza-
tion of the F pocket region. By using a refolded H-2Db in the 
presence of a pentamer peptide (NYPAL), which binds to the C 
to F pockets in the binding groove, a X-ray crystal structure of 
the pMHCI complex could be solved (79). Thus, peptide/class I 
interactions at the F pocket region seem to be sufficient to keep 
class I in a folded state. In agreement, short dipeptides mimick-
ing the peptide C-terminus of high-affinity ligands support the 
folding of HLA-A*0201, displaying high peptide-receptivity (14). 
To stabilize peptide-free class I in a folded form independently 
from the peptide, the Springer group created a novel variant by 
introducing a disulfide bond to restrain the high flexibility of the F 
pocket region. The disulfide mutant showed an increased peptide 
and β2m affinity and bypassed the cellular quality control (80).
MHC Class ii
Physiologically, the question if peptide-free MHC class II 
proteins play a role in adaptive immunity is posed by studies 
indicating that unloaded MHC class II proteins are abundantly 
present on the surface of immature DCs. There, they are able to 
bind ligands from the extracellular milieu and activate T cells 
(81, 82). Two isomers of peptide-unloaded MHC proteins 
seem to exist, each displaying different kinetic properties (83). 
While the peptide-receptive empty isomer of DR1 binds peptide 
rapidly, the conversion to the non-receptive isomer within less 
than 5  min dramatically reduces the peptide-binding capacity 
of human DR (41, 84, 85). Studies using circular dichroism 
and size exclusion chromatography predicted a conformational 
change of peptide-free MHC class II upon peptide binding, 
and an increase in the overall stability (44, 68, 86). Peptide-free 
MHC class II proteins thus show a lower degree of helicity and 
an increased hydrodynamic radius compared to peptide-loaded 
MHC class II.
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Carven and Stern studied ligand-induced conformational 
changes by selective chemical side-chain modification of 
peptide-free DR1 followed by mass spectroscopy analysis (87). 
The results of this study were inconsistent with a partly unfolded 
state of DR1 in the absence of ligand, but rather indicated a more 
localized conformational change induced upon peptide binding. 
However, empty MHC class II proteins harbor the hallmarks of 
partially unstructured peptide-binding domains when studied 
spectroscopically. NMR-spectra of the α-chain of such peptide-
free MHC class II proteins barely display any signals for residues 
corresponding to the folded peptide-binding groove, indicating 
that the binding groove undergoes conformational exchange 
(46). Taken together, it appears likely that the empty binding 
groove dynamically samples different native-like conformations. 
Interestingly, similar to MHC class I, certain small molecules 
and dipeptides increase peptide-receptivity of peptide-free MHC 
class II proteins, presumably by preventing a “closure” of the 
binding groove (88, 89). In similar to the F pocket of MHCI, the 
predicted site of interaction is the most dominant pocket of the 
binding groove (P1).
In a MD simulation study combined with peptide-binding 
assays, it was shown that a well-conserved residue, βN82, which 
also contributes disproportionally to pMHCII stability (12, 90), 
is participating in the control of peptide receptivity (91). The 
authors suggested that the “non-receptive” state of peptide-free 
DR1 is induced by a molecular lock through the formation of a 
hydrogen-bond between DRβ N82A and DRα Q9. The observed 
narrowing of parts of the binding groove-flanking α-helices likely 
represents the trigger for such a clamped conformation. Using 
MD simulations, another investigation suggested a movement of 
the α51–59 region into the P1–P4 site of the binding groove in 
the empty state. In this state, the α51–59 region adopted a ligand-
like conformation. In addition, an increased flexibility of the β2 
domain as well as the β50–70 helical region were observed (92). 
A higher flexibility of the β58–69 helical region was also seen in 
MD simulations of the HLA-DR3 protein upon in silico peptide 
removal (93) (Table 1). Interestingly, this helical segment is also 
recognized by monoclonal antibodies designed to bind to the 
peptide-free conformation (81, 94).
Finally, it has to be noted that the timescale of the experimen-
tal descriptions of empty MHC molecules differs vastly from the 
theoretical studies. While the latter describe the initial events 
of conformational changes accompanying peptide removal, the 
experimental investigations observe the properties of the empty 
MHC species at or near equilibrium.
DYNAMiC FeATUReS OF PePTiDe-
BOUND MHC COMPLeXeS
While the study of empty MHC proteins is of theoretical and 
conceptual interest, nature has engineered the antigen-presenting 
system in a way that prevents the accumulation of isolated, non-
peptide-bound MHC molecules. Endogenous peptides derived 
from the proteasome in case of class I or from the invariant chain 
in the case of class II first bind and eventually are replaced by 
antigenic peptide. This inherently dynamic process is enabled 
by intrinsic features of the MHC molecules and several studies 
suggest that pMHC complexes sample different and transient 
conformations dependent on the bound peptide and the allelic 
variant under investigation (46, 64, 71, 72, 95, 100, 106, 113, 114).
MHC Class i
Changes in conformational dynamics in MHC class I are het-
erogeneously distributed along its peptide-binding groove, as 
suggested by both computational and experimental studies. For 
example, MD simulations showed a subtype-dependent confor-
mational flexibility of the F pocket region. Residues 114 and 116 
of the HC, at the bottom of the F pocket, and residues 74 and 77 
from the α1-helix, engaging the peptide’s C-terminus, show an 
altered mobility in different MHC class I allotypes (9, 22, 70, 71, 
96, 115, 116). Consistently, it was shown that the dynamics of 
the MHC class I binding groove was most profoundly affected 
by C-terminal residues of the peptide (15). In longer MD simula-
tions, in addition to varying protein plasticity in the F pocket 
region, an enhanced sampling of conformations in the α3-domain 
upon peptide binding was observed (72, 73) (Table 1).
Experimental observations at the atomistic level, derived 
from NMR-based relaxation-dispersion experiments, have elu-
cidated the peptide dependency of minor states on the stability 
of pMHCI complexes. Conformational fluctuations of different 
HLA-B*35:01 complexes were localized to the peptide-binding 
groove, including residues of the B, E, and F-pocket, but not in 
the IgG-like domains (113). Interestingly, the presence of minor 
conformations in pMHCI complexes (ranging from approxi-
mately >1 to 4.5%) could be positively correlated to the thermo-
stability and surface presentation of the pMHCI complex under 
investigation, implying that a minor conformation considerably 
contributes to pMHCI stability. Similar, investigations of HLA-
A*02:01 loaded with different peptides by HD exchange/MS and 
fluorescence anisotropy revealed that fluctuations within the 
binding groove depend on the ligand bound to MHC class I (112). 
Despite these ligand-sensitive changes in dynamics, the α2-helix 
showed a general higher flexibility than the α1-helix. The authors 
concluded that the observed variations in dynamics throughout 
the peptide-binding site could influence receptor engagement, 
entropic penalties during receptor binding, and the population 
of binding-competent states (see also Table 2).
Another study also showed that β2m seems to sense allelic as 
well as peptide-induced conformational variations and accom-
modates to them, showing a high degree of plasticity within 
the inter-domain interface with the HC domains (110). NMR-
chemical-shift changes of complexes were most pronounced in 
the region close to the F-pocket. By comparing the dynamics 
in the ns–ms timescale of HC-bound and free β2m, Hee et  al. 
demonstrated that most residues gain rigidity upon HC bind-
ing (111). Nevertheless, three sites (region around His31, site 
around Asp53 and Lys58, and region around Ser88) remained 
flexible in the mature complex. Interestingly, His31 and Ser88 
are located underneath the F-pocket, which stability is known 
to be important for tapasin function. Moreover, Lys58 and Ser88 
are also known to interact with several other proteins, including 
the natural killer cell receptors Ly49A CD8 and LIR1 (117–119). 
Conformational sampling of these regions could thus be critical 
for the interaction with these receptors.
TABLe 1 | Computational studies on MHC class i and ii dynamics.
MHC Molecular dynamics parameters Outcome Reference
MHC class i
HLA-B*2705, HLA-B*2709 GROMACS, OPLS-AA/L, TIP4P, 310K Polymorphism of major histocompatibility class I (MHC class I) 
influences the dynamics of the binding groove and the bound 
peptide
Pohlmann et al. (95), Fabian 
et al. (96), and Narzi et al. (71)
HLA-A*02:01, HLA-B*44:02, 
HLA-B*44:05
Amber, parm03, TIP3P, 300K Peptide-free MHC class I shows a varying flexibility at the F 
pocket region
Zacharias and Springer (9) and 
Sieker et al. (70)
HLA-A2:01, H-2Kb Amber, parm03, TIP3P, 300K Prominent role of peptide C-terminus in long-range 
stabilization of MHC class I binding groove
Saini et al. (14) and Abualrous 
et al. (15)
HLA-B*44:02, HLA-B*44:05, 
H-2Kb, HLA-B*2705, 
HLA-B*2709
(Amber, parm03, TIP3P, 300K) 
(GROMACS, Amber99SB-ILDN, TIP3P, 
300K)
Dynamics of the F pocket region is important for MHC stability 
and modulates MHC class I tapasin dependance
Garstka et al. (21), Hein et al. 
(80), Abualrous et al. (22), 
Fleischmann et al. (37), and 
Fisette et al. (29)
BF2*15:01, BF2*19:01, 
HLA-B*44:02, HLA-B*44:05
GROMACS, Amber99SB-ILDN, TIP3, 
300K
MHC intrinsic plasticity determines the bound peptide and 
can be modulated allosterically by tapasin
Bailey et al. (72, 73)
HLA-A2:01, HLA-B*3501, 
HLA-B*3508
(GROMACS, GROMOS43a1, SPC, 
300 K) (NAMD, CHARMM22, TIP3P, 
300K)
Peptide-MHC dynamics determine the T cell receptor (TCR) 
binding mode
Cuendet et al. (97) and Reboul 
et al. (98)
HLA-B*2705, HLA-B*2709, 
H-2Db
(GROMACS, OPLS-AA/L, TIP4, 310 K) 
(Amber, parm03, TIP3P, 350K)
Peptide-MHC interactions at the A pocket region modulate 
TCR recognition
Nurzia et al. (99) and 
Uchtenhagen et al. (100)
H-2Ld NAMD, CHARMM27, TIP3P, 310K Peptide-receptive MHC class I shows a varying flexibility at 
the A pocket region
Mage et al. (74)
HLA-A2:01 (Normal mode analysis) (Modified 
Amber force fields, 300K)
Anti-correlative motion of residues in the binding groove is 
important for peptide binding “dynamic fit”
Nojima et al. (101)
MHC class ii
HLA-DR1, HLA-DR1 GROMACS, GROMOS9643a1, 
SPC, 298 K, GROMACS, GROMOS 
(ffG43a1), SPC, 310K
Peptide-free MHC class II show a large conformational 
flexibility around the P1 pocket
Painter et al. (92), Painter et al. 
(35), and Rupp et al. (91)
HLA-DR1 (1DLH) GROMACS, GROMOS, 310K Occupation of P1 with an amino acid side chains prevents 
the “closure” of the empty peptide binding site into the non-
receptive state
Gupta et al. (89)
HLA-DR3, HLA-DR1 (Amber, parm03, TIP3, 300K) 
(GROMACS, GROMOS, SPC3, 310K)
Prominent role of peptide N–terminus in long-range 
stabilization of MHC class II binding groove
Knapp et al. (102) and Yaneva 
et al. (93)
I-Au, HLA-DR1 HLA-DR4 GROMACS, GROMOS, SPC3, 310K Peptide-MHC dynamics influences T cells costimulation Knapp et al. (103) and Knapp 
et al. (104)
HLA-DR4 GROMACS, GROMOS96, SPC, 310K Different dynamics of soluble and membrane anchored pMHC Bello and Correa-Basurto (105)
The membrane anchored is more conformationally and 
energetically stable
HLA-DR1 NAMD, CHARMM22, explicit water 
model, 298K
Conformational entropy of peptide binding to DR1 correlates 
with the DM-susceptibility
Ferrante et al. (106)
HLA-DR1 ACEMD, ff99SB, TIP3P, 310K β-chain around peptide N-terminus and αW43 sample 
DM-bound-like conformations
Wieczorek et al. (46)
HLA-DR1 (Normal mode analysis) (Modified 
Amber force fields, 300K)
Anti-correlative motions in the binding groove is important for 
binding of long peptides “dynamic fit”
Nojima et al. (107)
HLA-DR1 (Normal mode analysis) (Modified 
Amber force fields, 300K)
The membrane-proximal domains of ~MHC class II modulate 
the dynamics of P1 pocket and have a greater influence on 
the binding groove than those of MHC class I
Nojima et al. (108)
MHC I, major histocompatibility class I.
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MHC Class ii
A similarly heterogeneous picture in regards to altered binding 
groove dynamics can be observed for MHCII: by dissecting the 
thermodynamics of peptide MHC class II interactions, Ferrante 
et  al. conclusively demonstrated how dynamics of pMHCII 
complexes are linked to peptide affinity and DM-susceptibility 
(106). Using different biophysical techniques and MD simula-
tions, the authors showed that peptide binding events can be 
driven by a considerable proportion of conformational entropy 
(if enthalpic interactions are less favored). MD simulations 
suggest that peptide-dependent conformational fluctuations 
involve alterations of α-chain residues DR1α-43–54 and 
TABLe 2 | experimental studies on major histocompatibility complex (MHC) class i and ii dynamics.
MHC Method Outcome Reference
MHC class i
HLA-B*2705, HLA-B*2709 IR spectroscopy, crystallography The heavy α-chain (HC) of B27:05 shows a higher flexibility than that of 
B27:09
Fabian et al. (109)
HLA-B*2705, HLA-B*2709 1H-15N-HSQC (NMR) HLA-B27 polymorphism influences the β2m plasticity at the HC/β2m interface Beerbaum et al. (110)
HLA-Cw*07:02 1H-15N-HSQC (NMR) Peptide binding domains are “unstructured” in the peptide-free form Kurimoto et al. (77)
HLA-B*2709 T1/T2 and HetNOE measurements Regions of β2m remain flexible upon HC binding Hee et al. (111)
HLA-A2 HDX/MS combined with 
fluorescence anisotropy
Fluctuations within the binding groove depend on the ligand bound to MHC 
class I
Hawse et al. (112)
HLA-B*35:01 NMR (relaxation-dispersion) Stability of pMHC class I is determined by peptide-dependent fluctuations 
defining minor states
Yanaka et al. (113)
MHC class ii
HLA-DR1 HDX combined with mass 
spectroscopy
310 helix shows a conformational lability Painter et al. (35)
DM-susceptible conformations show weakened interactions around the 
P1-pocket
HLA-DR1 NMR combined with 
crystallography
Peptides can bind in an bidirectional mode to DR1 Gunther et al. (57)
HLA-DR1 SACS, NMR, crystallograpy Susceptibility to HLA-DM depends on a dynamic conformation of pMHC 
class II
Yin et al. (64)
HLA-DR1 NMR detected HDX, HSQC 
spectra
Dynamics in helical segments and and αS2/S4 strand of binding groove Wieczorek et al. (46)
Peptide binding domains are “unstructured” in the peptide-free form
HDX, hydrogen/deuterium (H/D) exchange; HSQC, heteronuclear Single Quantum Coherence; SAXS, small-angle X-ray scattering.
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β-chain residues 63–68 and 79–90. Wieczorek et al. performed 
H/D-exchange measurements in combination with NMR spec-
troscopy to obtain residue-specific experimental information 
about the stability of individual secondary structure elements. 
Several regions undergoing conformational fluctuation even 
in highly stable pMHCII complexes were thus revealed. 
These fluctuations are confirmed by extensive (~100 μs) MD 
simulations and Markov model analyses that reveal transient 
conformations with obvious relevance for the peptide-exchange 
pathway (see below for details) (46). In particular, the highest 
lability was seen in DRα 46–62, in parts of β-strands s2–s4 
sitting underneath the N-terminal part of the α1 helix, β65–93 
and several loops connecting the β-strands of the peptide-
binding site. Interestingly, this experimental piece of evidence 
is also in line with the global B-factor analysis presented 
here (Figure  2B); a certain degree of dynamics thus seems 
to already be encoded even in the context of a high affinity 
pMHC complex. Earlier on, it was shown by HD-exchange/MS 
measurements that conserved peptide–MHC class II contacts 
(H–bonds) are strong at the P1 pocket-proximal site of the 
peptide (especially position βN82) in highly stable immuno-
dominant complexes, which is in agreement with previous 
biochemical studies (12, 35, 90). However, local destabilization 
induced by a point mutation in the DR1 complex and the use 
of a different ligand (DR1-αF54C/CLIP) strongly enhanced 
fluctuations of the peptide and especially weakened contacts 
around the P1 site (35). This implies that weakening interac-
tions by substitutions in the peptide or MHC (allelic variation) 
would have an influence on conformational fluctuations that 
correlate with DM-susceptibility.
MHC DYNAMiCS DURiNg PePTiDe 
eXCHANge
While the studies described in the previous section unambigu-
ously demonstrate the dynamic features of pMHC complexes, the 
question arises naturally in how far these properties translate into 
peptide exchange. For pMHCII complexes experimental progress 
has been made in identifying intermediate or transient confor-
mations of pMHCII with regard to catalyzed or intrinsic peptide 
exchange (13, 31, 32, 35, 46). For pMHCI molecules the atomistic 
description of structural changes during peptide exchange mostly 
relies on MD simulation studies, supported by mutational analysis 
and circumstantial biophysical evidence (14, 22, 37, 73).
MHC Class i
Within cells, tapasin is a key protein that mediates the binding 
of high-affinity peptides to most class I proteins. To date, there is 
no crystal structure of the tapasin/MHC class I complex. Based 
on mutational studies, however, two regions have been shown 
to be essential for tapasin interaction with the HC of MHC class 
I: a loop in the α3 domain (residues 222–229) and a part of the 
α2 domain (residues 128–137) (17, 23, 25, 120, 121). Two major 
functions have been proposed for tapasin: (i) a chaperone-like 
stabilization of empty class I proteins (20–22, 24, 122) and (ii) a 
peptide-editing function through peptide-exchange catalysis (26, 
123, 124). Several computational models have been published to 
describe the mechanism of action of tapasin on MHC class I (28, 
29, 121). Most researchers agree on the importance of the F-pocket 
region for peptide exchange (14, 21, 37, 80, 125). However, the 
association of F-pocket dynamics and the peptide-exchange 
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mechanism remain a matter of debate. So far, dynamics in the 
F-pocket region in the presence of peptide have not revealed any 
significant conformational exchange phenomena in most MD 
simulations (Table 1). Recently, longer MD simulations (micro-
second timescale) of tapasin/pMHCI complexes indicated that 
binding of tapasin to HLA-B*44:02 accelerates the dissociation 
of low-affinity peptides (29, 37). Using a computational systems 
model (73, 126), it was shown that peptide exchange seems to 
depend on the opening and closing rate of the binding groove 
in the presence of peptide. According to this study, the pMHCI 
opening rate is peptide-dependent, but pMHCI closing is allele-
dependent. Consequently, a low-affinity peptide complex would 
display fast opening rates, but only if the MHC allele variant has 
an F-pocket signature (more plasticity) that allows for fast closing 
in the presence of a high-affinity peptide (as B44:05), it would 
lead to efficient peptide exchange in the absence of catalyst. Allele 
variants with a rigid F-pocket conformation (as B44:02) in con-
trast depend on tapasin to sample the necessary conformational 
states to close the binding groove quickly.
It has to be considered that as a default, tapasin is present in 
the cell and that it may also provide the necessary function as a 
chaperone to prevent the collapse of empty MHC class I mol-
ecules into a non-receptive state (29, 127) as it is experimentally 
measured in tapasin-deficient cells (21, 22). However, in the 
absence of a crystal structure of the tapasin/MHC class I complex, 
it is difficult to rationalize the dynamics with regard to tapasin 
binding and exchange.
MHC Class ii
Two seminal studies made it unambiguously clear that HLA-DM 
recognizes complexes showing a P1-destabilized conformation 
(13, 31). However, since DM-susceptible structures rarely show 
any of the changes present in the DM-bound structure (e.g., 
folding of α-46–55 into an α-helix and unfolding of C-terminal 
β-helix), the question of the conformational prerequisites for 
DM binding arises. As mentioned previously, an important 
study indeed demonstrated that HLA-DM attacks pMHC class 
II complexes at a site of conformational lability, the 310-helical 
region (35). This segment, together with a neighboring unstruc-
tured segment (α52–55) folds into an α-helix when bound to DM 
(31). Interestingly, increased fluctuations of this region could 
be observed by other computational and experimental studies, 
implying the existence of higher conformational entropy within 
this region (46, 106). Noteworthy, the α-helix in the region 
β86–β91 opens up to a certain degree in the DM-bound structure 
of DR1. However, a considerable influence of P1-remote sites on 
conformational dynamics and DM-dependence was recently 
demonstrated (64). In this study, alteration of P9-pocket/pep-
tide interactions influenced dynamics of the pMHCII, likely in 
regions relevant for DM binding. The authors concluded that the 
key determinants for HLA-DM recognition are conformational 
dynamics present in HLA-DR1. Similarly, and as already men-
tioned above, Ferrante et al. explained the relationship between 
entropic penalties and DM binding in a thermodynamic context 
(106). According to their experimental and computational results, 
higher conformational entropy of pMHCII complexes correlates 
with DM susceptibility.
A recent study by our group in the MHC class II field explored 
internal motions of pMHC class II molecules along the confor-
mational peptide-exchange pathway in a more conceptual model 
(46). Using NMR/HDX (hydrogen deuterium exchange) and 
MD simulations of over 200 μs in total, followed by Markov State 
model (MSM) analysis (128–132), we have identified transient 
conformations relevant for the DM-catalyzed and non-catalyzed 
(spontaneous) peptide-editing process (46). In agreement with 
the general view, the catalyzed pathway depends on the particular 
destabilization of the region surrounding the P1 pocket, sharing 
in part features of MHC class II bound to DM. More specifically, 
it has been suggested for MHC class II that pMHC complexes 
have to sample P1-pocket-destabilized conformations to allow 
for HLA-DM binding (13).
The non-catalyzed pathway, however, was correlated to the 
ground state of the pMHCII complex and, therefore, is directly 
correlated with thermodynamic stability. Indeed, it was shown 
that, removal of two hydrogen bonds between β82N of the MHC 
class II and the backbone of the peptide in the mutant DR1βN82A 
drastically reduces stability and, at the same time, dramatically 
enhances non-catalyzed peptide exchange. Nevertheless, binding 
to HLA-DM is also enhanced for the βN82A mutant, leading 
to the somewhat paradoxical finding that an MHCII molecule 
might bind tightly to a catalyst that it does not need for exchang-
ing peptide. This can be best conceptualized when assuming 
that the βN82A mutant of HLA-DR1 in addition to increased 
spontaneous exchange more frequently samples a rare conforma-
tion along the pathway of catalyzed exchange. MD simulations 
in conjunction with MSM analysis indeed show that an excited 
state structurally correlated with features of the HLA-DM bound 
conformation. This excited state was seen to be significantly more 
frequently sampled in the mutant compared to WT HLA-DR1.
However, a similar intermediate state can be defined for the 
very stable WT protein, where peptide release from the pockets 
was not mandatory for the observation of the early intermedi-
ates. Thus, if the pMHCII forms a stable complex, the peptide 
editing depends on the population of rare conformations that can 
be selected by the catalyst DM for binding. This study demon-
strated the critical importance of residues 80–93 of the β1 helix 
for catalyzed exchange, suggesting that β1 helical unfolding is 
critical for the rearrangement of this segment as it is observed 
in the DR1-DM structure (31). As the study shows, mutations in 
the β1 helix (e.g., βE87P) designed to specifically destabilize the 
C-terminal part of the β1 helix without disrupting H-bonds to the 
peptide, are able to over-proportionally shift the dynamics toward 
the HLA-DM-dependent pathway (46).
In conclusion, this model helps to reconcile discrepancies in 
the hypothesized correlations of peptide affinity, pMHC stability, 
DM susceptibility, and catalytic effect (133).
CONCLUSiON AND OUTSTANDiNg 
QUeSTiONS
Major histocompatibility complex proteins are encoded by oligo-
genic and highly polymorphic genes and most polymorphisms 
map to the regions important for peptide binding. The pMHC 
complexes display various degrees of flexibility along the binding 
FigURe 4 | Thermodynamic model for peptide exchange of major histocompatibility complex (MHC) class i. Peptide–MHC class I (pMHCI) complexes 
can follow two mechanistic pathways for peptide exchange starting from pMHCI ground state (state 1). In the tapasin-catalyzed pathway, tapasin modulates 
conformational changes in the α2-1 helix (red) of the F pocket region (pink) and the α3 domain (not shown) that accelerate the kinetics of peptide dissociation (state 
2) and the loading of a high-affinity peptide (3). More intermediates states (between state 1 and state 3) need to be identified by computational studies and/or NMR 
and X-ray crystallography. In the non-catalyzed pathway, the peptide dissociates from the sub-optimally-loaded intermediate state (state 1′). The resulting empty 
MHC molecule shows subtype-dependent dynamics (especially at the F pocket region, pink) and thus can exist in a stable peptide-receptive form (state 2′) or in an 
unstable form (state 2″) that is chaperoned by tapasin for peptide binding. The structures used in states 1 and state 3 were modified from PDB: 1UXS (shown in 
white). The models used in states 1′, 2, 2′, and 2″ represent suggested states by computational and experimental studies (shown in limon).
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groove, and these dynamic features seem to correlate with the 
propensity for peptide exchange. Of interest is the fact that tapa-
sin and DM both bind their MHC targets in regions of enhanced 
dynamics. Short, destabilized helical segments together with their 
adjacent structural elements seem to represent the requirements 
for transient binding of the respective catalyst. The degree of 
these local flexibilities can be correlated to a higher dependence 
of a particular pMHC complex on tapasin or DM. Polymorphic 
substitutions might not only change the binding preference for 
certain ligands but also the overall stability and dynamics of 
the corresponding allelic variants. In turn, this will affect the 
conformational ensemble recognized by the peptide editors and 
in principle should be able to explain why certain alleles seem to 
possess a generally lower taspasin or DM dependence. In this way, 
MHC molecules may become a paradigmatic example of how dif-
ferences in the dynamic landscape of protein complexes translate 
into distinct functional outcomes of physiological relevance.
How far have we come and what has to be done to achieve this 
goal? Figures 4 and 5 summarize the findings described in this 
review and also emphasize the most daunting questions in the 
field that need to be answered in order to formulate a unifying 
concept of antigen exchange. What seems to be clear is that both 
type of MHC molecules can exchange peptide along two distinct 
pathways, with the ratio of spontaneous versus catalyzed exchange 
certainly being different for the allelic protein variants and pMHC 
complex. While dynamics often correlates with thermodynamic 
stability, it has yet to be seen which type of motions are critical for 
catalysis and which structural elements are indispensable for these 
transitions to occur. For MHC class II molecules, the structure 
of the MHCII–DM complexes provides a cornerstone (31), and 
the early intermediates (μs-ms timescale) toward the DM-bound 
form could be defined (35, 46) (Figure  5). However, there are 
no structural insights about the replacement of DM by incoming 
peptide, thus requiring experimental and simulation strategies to 
follow the fate of DM-prebound MHCII molecules. In the case 
of MHCI, a tapasin-class I complex structure is required in order 
to provide a reliable framework for further experimental and 
theoretical studies. Similarly, characterization of empty MHC 
molecules will certainly aid in defining the dynamic modes 
that are explored by the peptide-binding domains. Since it has 
been shown that empty MHC molecules can be rescued by the 
chaperoning function of the exchange catalysts (134, 135) and 
thus the dynamics that occur upon peptide exchange are likely 
to show features of the empty state. It seems, therefore, highly 
desirable to compare the two systems on time scales down to a 
few milliseconds.
FigURe 5 | Thermodynamic model for peptide editing of major histocompatibility complex class ii. pMHCII complexes can follow two mechanistic 
pathways for peptide exchange. The DM-catalyzed route requires multi-step transitions starting from the pMHCII ground state (1). This includes initially an out-flip 
movement of αW43 or the destabilization of β80–93 region via spontaneous conformational sampling of rare conformations (state 2′). DM would preferably select for 
conformations that are sampled on longer timescales and which show both, an out-flip movement of αW43 and a destabilized β80–93 region. Binding of DM to the 
energetically excited intermediate (which shows in part features of the DM-bound state) would then induce further rearrangements in the 310-helical region (state 3′) 
and thereby accelerate peptide-release. Binding of peptides which can displace the stabilizing interactions complete the peptide exchange process (state 4). 
Spontaneous (non-catalyzed) peptide exchange depends on the intrinsic stability of the pMHCII complex and does not rely on the sampling of rare conformations 
(state 2). Binding of a new peptide would likely require dissociation of the bound peptide, leading to the empty state (state 3) which rapidly converts into the 
non-receptive state (state 3b) but can also be chaperone by DM (state 3c) in order to allow for high-affinity peptide binding (state 4). Structures used in state 1, 3′, 
and 4 were derived from PDB: 4QXA, 4FQX, and 1DLH, respectively. Cartoons shown in 2, 2′, 3, and 3b were derived from molecular dynamic simulations (46, 91).
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For both MHC classes, more sophisticated NMR experiments 
capitalizing on selective amino acid side-chain labeling protocols 
are probably required and methods relying on CEST or relaxation 
dispersion should be able to yield more direct information on the 
anticipated intermediate states (136, 137). So far, in-depth NMR 
experiments are restricted to certain stable pMHC complexes 
and the investigation of other alleles have been hampered by 
the in-availability of other variants such as the disease-relevant 
DQ alleles. There is a need to expand the experimental basis of 
dynamically investigated pMHC complexes in order to test the 
predictions made on the basis of the dynamic features of just a few 
alleles. Solutions are most likely to come from protein engineering 
approaches in combination with the use of different expression 
systems. The increasing importance of MD simulations arises 
from the fact that micro-to-milli-second simulations in combina-
tion with Markov State Modeling will become more of a standard 
in the field. This is essential, because the critical intermediates of 
antigen exchange seem to be populated at this time scale. Once we 
are able to conceptualize conformational peptide exchange, we 
will be in the position to better predict MHC peptide occupancies 
in the context of cellular editing mechanisms and we will under-
stand and be able to manipulate the action of small molecules or 
biological macromolecules that modulate peptide exchange.
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